ChitogenX Inc.

OTC: CHNXF · Healthcare · Biotechnology

Canadian filerHQ Kirkland, QCReports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 24

v0.1 · 5/100 weight · pillars only

↑ disclosure history, market scale · ↓ balance-sheet leverage, Altman-Z

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$1.2M

Employees

Market cap

$627.6k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$00 CAD2024

Net income-$1.2M-1.6M CAD2024

Operating income-$2.1M-2.8M CAD2024

Total assets$398.6k534.0k CAD2024

Liabilities$5.0M6.7M CAD2024

Equity-$4.6M-6.2M CAD2024

Revenue trend

FY2017 – FY2024 · USD

FY17

FY18

FY19

FY20

FY21

FY22

FY23

FY24

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

ChitogenX Inc. booked $0 in FY2024 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Concord Medical Services Holdings Limited58C Molecule Holdings Inc.——StageZero Life Sciences Ltd.——Pharmagreen Biotech Inc.——

Key facts

CEOPierre Laurin

SectorHealthcare

IndustryBiotechnology

HeadquartersKirkland, QC

ExchangeOTC: CHNXF

Employees5

IPO date2020-10-06

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.